Literature DB >> 12370807

Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.

Stanley C W Ko1, Keith S Chapple, Gillian Hawcroft, P Louise Coletta, Alexander F Markham, Mark A Hull.   

Abstract

In human colorectal adenomas or polyps, cyclooxygenase-2 is expressed predominantly by stromal (or interstitial) macrophages. Therefore, we tested the hypothesis that macrophage cyclooxygenase-2 has paracrine pro-tumorigenic activity using in vitro models of macrophage-epithelial cell interactions. We report that macrophages can promote tumorigenic progression of intestinal epithelial cells (evidenced by decreased cell-cell contact inhibition, increased proliferation and apoptosis, gain of anchorage-independent growth capability, decreased membranous E-cadherin expression, up-regulation of cyclooxygenase-2 expression, down-regulation of transforming growth factor-beta type II receptor expression and resistance to the anti-proliferative activity of transforming growth factor-beta(1)) in a paracrine, cyclooxygenase-2-dependent manner. Pharmacologically relevant concentrations (1-2 microM) of a selective cyclooxygenase-2 inhibitor had no detectable, direct effect on intestinal epithelial cells but inhibited the macrophage-epithelial cell signal mediating tumorigenic progression. Cyclooxygenase-2-mediated stromal-epithelial cell signalling during the early stages of intestinal tumorigenesis provides a novel target for chemoprevention of colorectal cancer (and other gastro-intestinal epithelial malignancies, which arise on a background of chronic inflammation, such as gastric cancer) and may explain the discrepancy between the concentrations of cyclooxygenase inhibitors required to produce anti-neoplastic effects in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370807     DOI: 10.1038/sj.onc.1205869

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Conditional regulation of cyclooxygenase-2 in tracheobronchial epithelial cells modulates pulmonary immunity.

Authors:  G Y Park; N Hu; X Wang; R T Sadikot; F E Yull; M Joo; R S Peebles; T S Blackwell; J W Christman
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

2.  Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells.

Authors:  Gillian Hawcroft; Paul M Loadman; Andrea Belluzzi; Mark A Hull
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

3.  Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation.

Authors:  Devashish Kothapalli; Ilia Fuki; Kamilah Ali; Sheryl A Stewart; Liang Zhao; Ron Yahil; David Kwiatkowski; Elizabeth A Hawthorne; Garret A FitzGerald; Michael C Phillips; Sissel Lund-Katz; Ellen Puré; Daniel J Rader; Richard K Assoian
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

4.  Cytotoxic Profiling of Endogenous Metabolites Relevant to Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) on p53 Variant Human Colon Carcinoma Cell Lines.

Authors:  Dusan Vukmirovic; Colin Seymour; Dave Rollo; Carmel Mothersill
Journal:  Dose Response       Date:  2018-08-09       Impact factor: 2.658

5.  Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells.

Authors:  S H Gardner; G Hawcroft; M A Hull
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

Review 6.  Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2.

Authors:  Ioannis A Voutsadakis
Journal:  J Cell Mol Med       Date:  2007 Mar-Apr       Impact factor: 5.310

7.  Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc Min/+ mouse model of intestinal tumorigenesis.

Authors:  Mark A Hull; Richard J Cuthbert; C W Stanley Ko; Daniel J Scott; Elizabeth J Cartwright; Gillian Hawcroft; Sarah L Perry; Nicola Ingram; Ian M Carr; Alexander F Markham; Constanze Bonifer; P Louise Coletta
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.